Live Chat
Today's Hours: 8:00am - 8:00pm
Lane Medical Library

Search

Filter Results

Did You Mean:

Search Results

Sort by
relevance
  • Database
    Summary: Provides detailed, evidence-based decision trees and a step-by-step approach, covering prevention, diagnosis, treatment and prognosis. Incorporates guidelines, systematic reviews from BMJ Clinical Evidence, and content from Cochrane Clinical Answers and AHFS Drug Information Essentials.
    Digital Access BMJ Database
  • Book
    written by Li Wenhua and Zhao Xianying ; translated by Penny Edwards.
    Print c1989
  • Article
    Di Carlo FJ, Leinweber FJ, Szpiech JM, Davidson IW.
    Clin Pharmacol Ther. 1977 Dec;22(6):858-63.
    The metabolism of l-bunolol, a new beta-blocking drug, was studied in man after single oral 3-mg doses of 3H-labeled compound. Absorption from the gut was rapid and virtually complete. Peak levels of bunolol and of dihydrobunolol, an active metabolite, were observed at 1 hr. Excretion of the administered radioactivity was mainly into the urine (78% in 4 days), with only 3% appearing in the feces. Bunolol, bunolol glucuronide, bunolol sulfate, dihydrobunolol, and dihydrobunolol glucuronide were identified and quantified in the plasma. These compounds represented 82% of the radioactivity in plasma at 30 min and 55% at 24 hr. Plasma half-lives (+/-S.D.) were estimated to be 6.1 +/- 0.3 hr for bunolol, 9.1 +/- 1.9 hr for bunolol glucuronide, 17.4 +/- 2.5 hr for bunolol sulfate, 7.1 +/- 0.5 hr for dihydrobunolol, and 7.7 +/- 0.8 hr for dihydrobunolol glucuronide.
    Digital Access Access Options